Paper39875017
Targeted gut microbiome therapy: Applications and prospects of probiotics, fecal microbiota transplantation and natural products in the management of type 2 diabetes.
Qin L and 6 others. Pharmacol Res, 2025. Cited by 25 papers, by iCite.
Cite this record
ConductScience Library. Targeted gut microbiome therapy: Applications and prospects of probiotics, fecal microbiota transplantation and natural products in the management of type 2 diabetes. Papers, record 39875017. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39875017
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Targeted gut microbiome therapy: Applications and prospects of probiotics, fecal microbiota transplantation and natural products in the management of type 2 diabetes.
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Diabetes Mellitus, Type 2 | Major topic |
| Fecal Microbiota Transplantation | Major topic |
| Gastrointestinal Microbiome | Major topic |
| Probiotics | Major topic |
| Biological Products | Major topic |
| Humans | |
| Animals |
Source PubMed
Cited by19
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 25 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42942889 | Natural Products in Diabetes Mellitus: A Narrative Review of Mechanistic Insights into Metabolic Regulation and Therapeutic Potential. | Nutrients | 2026 | https://conductscience.org/library/papers/42942889 | PubMed |
| 42843354 | Fecal Microbiota Transplantation Beyond Clostridioides difficile Infection: Expanding Indications, Mechanisms, and Future Directions. | J Korean Med Sci | 2026 | https://conductscience.org/library/papers/42843354 | PubMed |
| 42652170 | Guanxinning Tablet Ameliorates Erectile Dysfunction in Diabetes Mellitus Rats with Involvement of PI3K/Akt/FOXO1 Signaling Pathway Modulation. | Biomedicines | 2026 | https://conductscience.org/library/papers/42652170 | PubMed |
| 41972561 | The Metabolic Calibration of Female Immune Plasticity: From X-Linked Vulnerability to Precision Metabotyping. | Biology (Basel) | 2026 | https://conductscience.org/library/papers/41972561 | PubMed |
| 41900387 | Role of Gut Microbiota in Bridging Vitamin D Deficiency and Type 2 Diabetes Mellitus Pathogenesis. | Microorganisms | 2026 | https://conductscience.org/library/papers/41900387 | PubMed |
| 41843084 | Modulating gut microbiota in type 2 diabetes mellitus: advances and challenges in precision medicine. | Acta Diabetol | 2026 | https://conductscience.org/library/papers/41843084 | PubMed |
| 41762381 | Gut Microbiota and Metabolic Health: From Dysbiosis to Therapeutics. | Diabetes Ther | 2026 | https://conductscience.org/library/papers/41762381 | PubMed |
| 41725998 | 1-Deoxynojirimycin with theaflavins ameliorates high-fat diet-induced insulin resistance in mice by modulating the gut microbiota. | Front Nutr | 2025 | https://conductscience.org/library/papers/41725998 | PubMed |
| 41710512 | Novel probiotic Lactobacillus helveticus WIS02 alleviates diabetes through multi-pronged regulation of glycolipid metabolism, pancreatic protection and gut microbiota remodeling. | Front Microbiol | 2025 | https://conductscience.org/library/papers/41710512 | PubMed |
| 41694562 | Targeting the gut microbiome for type 2 diabetes management: a scoping review of systematic reviews and meta-analyses. | Front Endocrinol (Lausanne) | 2026 | https://conductscience.org/library/papers/41694562 | PubMed |
| 41459531 | Targeting the TLR4 axis with microbiota-oriented interventions and innovations in diabetes therapy: a narrative review. | Front Immunol | 2025 | https://conductscience.org/library/papers/41459531 | PubMed |
| 41457230 | Deciphering the association between dietary live microbe intake and metabolic syndrome: exploring the effects of inflammation and insulin resistance. | J Health Popul Nutr | 2025 | https://conductscience.org/library/papers/41457230 | PubMed |
| 41426511 | Glycemic Variability and Gut Microbiota Metabolic Patterns: A Novel Perspective on Diabetic Complications. | Food Sci Nutr | 2025 | https://conductscience.org/library/papers/41426511 | PubMed |
| 41299966 | Xanthoceras sorbifolium Bunge Leaves Ameliorate Type 2 Diabetes Mellitus by Modulating Glucolipid Metabolism Through the Gut Microbiota-Metabolite Axis. | Foods | 2025 | https://conductscience.org/library/papers/41299966 | PubMed |
| 41158622 | Treatment of T2DM-related inflammation and vascular injury by regulating cellular crosstalk in the islet microenvironment. | Front Endocrinol (Lausanne) | 2025 | https://conductscience.org/library/papers/41158622 | PubMed |
| 41008596 | Elderberry-Based Multifunctional Prebiotic Systems Prepared via Spray Drying. | Biomolecules | 2025 | https://conductscience.org/library/papers/41008596 | PubMed |
| 40755760 | Novel insights into ORFV B2L DNA vaccine-mediated gut microbiota modulation and immune augmentation in rats. | Front Immunol | 2025 | https://conductscience.org/library/papers/40755760 | PubMed |
| 40729002 | Plant Heteropolysaccharides as Potential Anti-Diabetic Agents: A Review. | Curr Issues Mol Biol | 2025 | https://conductscience.org/library/papers/40729002 | PubMed |
| 40574831 | The gut-immune axis in primary immune thrombocytopenia (ITP): a paradigm shifts in treatment approaches. | Front Immunol | 2025 | https://conductscience.org/library/papers/40574831 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39875017
GET https://conductscience.org/api/papers/v1/39875017/authors